SAB Biotherapeutics, Inc. Common Stock (SABS) Stock Price

SABSStock

$2.53+16.59%52W

Market Cap$230.20M

P/E17.34x

PEG Ratio—

Div yield—

Beta0.81

SABS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-44.36%

Price vs S&P 500 (4W)-24.04%

VGM Score31.98

P/E Ratio (Annual)17.34x

Book Value / Share (Quarterly)$2.57

P/TBV (Annual)1.52x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-72.10%

Cash Flow / Share (Quarterly)$-0.69

Price vs S&P 500 (YTD)-44.28%

Net Profit Margin (TTM)-1795.85%

EPS (TTM)$-1.42

10-Day Avg Trading Volume0.77M

EPS Excl Extra (TTM)$-1.42

EPS (Annual)$0.22

ROI (Annual)8.58%

Net Profit Margin (5Y Avg)-906.73%

Cash / Share (Quarterly)$1.23

P/E Basic Excl Extra (TTM)17.34x

EPS Growth (5Y)-50.72%

P/E Normalized (Annual)17.34x

ROA (Last FY)7.68%

Revenue Growth TTM (YoY)-92.42%

EBITD / Share (TTM)$-1.35

ROE (5Y Avg)-60.20%

Operating Margin (TTM)-2388.92%

Cash Flow / Share (Annual)$-0.96

P/B Ratio1.07x

P/B Ratio (Quarterly)1.39x

Net Income / Employee (Annual)$154,300

EV / Revenue (TTM)170.19x

Net Interest Coverage (TTM)-52.02x

ROA (TTM)12.51%

EV / EBITDA (TTM)22.33x

EPS Incl Extra (Annual)$0.22

Current Ratio (Annual)9.46x

Quick Ratio (Quarterly)8.93x

3-Month Avg Trading Volume0.67M

52-Week Price Return16.59%

P/E Incl Extra (TTM)17.34x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.29

P/S Ratio (Annual)174.07x

Asset Turnover (Annual)0.03x

52-Week High$5.15

Operating Margin (5Y Avg)-1010.02%

EPS Excl Extra (Annual)$0.22

CapEx CAGR (5Y)-40.71%

26-Week Price Return-34.46%

Quick Ratio (Annual)9.13x

13-Week Price Return-28.53%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)9.22x

Enterprise Value$225.13M

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-2579.03%

Cash / Share (Annual)$2.03

3-Month Return Std Dev42.63%

Net Income / Employee (TTM)$154,300

EBITDA CAGR (5Y)-9.83%

ROE (Last FY)8.76%

Net Interest Coverage (Annual)-80.07x

EPS Basic Excl Extra (Annual)$0.22

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-1.42

Receivables Turnover (Annual)0.00x

ROI (TTM)14.61%

P/S Ratio (TTM)174.02x

Pretax Margin (5Y Avg)-906.71%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.62

Price vs S&P 500 (52W)1.06%

P/E Ratio (TTM)17.34x

Year-to-Date Return-32.35%

5-Day Price Return-10.60%

EPS Normalized (Annual)$0.22

ROA (5Y Avg)-35.54%

Net Profit Margin (Annual)-2579.03%

Month-to-Date Return-20.19%

Cash Flow / Share (TTM)$-0.47

EBITD / Share (Annual)$-0.79

Operating Margin (Annual)-3244.87%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-53.03%

P/E Excl Extra (TTM)17.34x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.42

P/TBV (Quarterly)3.09x

P/B Ratio (Annual)1.18x

Pretax Margin (TTM)-1795.85%

Book Value / Share (Annual)$3.18

Price vs S&P 500 (13W)-31.22%

Beta0.81x

Revenue / Share (TTM)$0.00

ROE (TTM)15.17%

52-Week Low$2.10

vGradeD

gGradeF

mGradeC

vgmGradeD

SABS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.28	-$0.28	-0.99%(-$0.00)
Q4 2025	Mar 9, 2026	-$0.17	-$0.41	-142.12%(-$0.24)
Q3 2025	Nov 14, 2025	-$0.46	$0.50	+209.09%(+$0.96)
Q2 2025	Aug 7, 2025	-$0.80	-$1.09	-36.93%(-$0.29)

SABS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.38

4.35

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SABSSAB Biotherapeutics, Inc. Common Stock	D	F	C	174.0x	-92.4%	—	-50.7%	$2.53
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About SAB Biotherapeutics, Inc. Common Stock

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing targeted human polyclonal antibodies using its DiversitAb platform, which leverages genetically engineered cattle to produce large quantities of fully human antibodies without human plasma or serum. This differentiated approach enables rapid, scalable production for therapeutic applications.